To evaluate the therapeutic efficacy of NK92-Neo2/15-OX40L expanded NK cells in vivo, killing assays were performed on HepG2 (liver cancer), A427 (lung cancer) and CAVO3 (ovarian cancer) derived xenograft models. The gene discussed is TNFSF4; the disease is lung cancer.